Bladder Cancer - Results from #760

REVIEW UroToday

Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry. November 3, 2023

FGFR Genomic Alterations and Response to Erdafitinib - Expert Commentary November 2, 2023

Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer. November 2, 2023

Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics. November 2, 2023

Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer. November 1, 2023

US Clinical Practice Patterns of Intravesical Chemotherapy for BCG-Unresponsive and BCG-Exposed Non-muscle Invasive Bladder Cancer. November 1, 2023

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. October 31, 2023

Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images. October 31, 2023

Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy. October 31, 2023

Recent Patterns in Global Incidence and Mortality for Bladder Cancer - Expert Commentary October 30, 2023

The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. October 30, 2023

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. October 30, 2023

Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer. October 30, 2023

Bladder cancer. October 30, 2023

Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. October 27, 2023

Rational peri-operative management of antithrombotic therapy in patients undergoing radical cystectomy: A 30-day morbidity analysis based on the updated European Association of Urology guidelines for standardized complication reporting. October 27, 2023

Enfortumab Vedotin Versus Chemotherapy for Advanced Urothelial Carcinoma - Expert Commentary October 26, 2023

How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? October 26, 2023

Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma. October 26, 2023

Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. October 25, 2023

Page 39 of 517